Edited by Prof Weijing Sun
Due to recent technological and scientific advancements, the past few years have seen dramatic breakthroughs in the burgeoning field of immunotherapy. These and future advances in immunotherapy have the potential to transform cancer treatment and the lives of patients.
This thematic series, published in the Journal of Hematology & Oncology, covers some of the recent advances in cancer immunotherapy.
As discussed by Prof Weijing Sun in the Editorial, important issues addressed by the authors in this series include: the identification of clinically relevant predictive and prognostic biomarkers to help define subgroups of patients who are most likely to benefit from various immunotherapies; management of immunotherapy-related toxicities and resistance; and future directions and approaches.
Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success ...
Citation: Journal of Hematology & Oncology 2017 10:151